Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a
terapii imunosupresoare, la pacienţii adulţi
Yüklə 4,39 Mb.
|
- Bu səhifədəki naviqasiya:
- Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic
- SUBLISTA C2 - P9: PROGRAM NAŢIONAL DE TRANSPLANT DE ORGANE, ŢESUTURI ŞI CELULE DE ORIGINE UMANĂ. P9.4 TRANSPLANT RENAL, TRANSPLANT COMBINAT RINICHI ŞI PANCREAS
| terapii imunosupresoare, la pacienţii adulţi.
Profilaxia rejetului de grefă la pacienţii care primesc transplant hepatic alogen. Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului. ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA05 TACROLIMUSUM CAPS. ELIB. PREL 0,5 mg ADVAGRAF 0,5 mg 0,5 mg ASTELLAS PHARMA GMBH
PROGRAF(R) 0,5 mg 0.5 mg ASTELLAS PHARMA GMBH L04AA05 TACROLIMUSUM CAPS. 1 mg PROGRAF(R) 1 mg 1 mg ASTELLAS IRELAND CO. LTD. L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 1 mg ADVAGRAF 1 mg 1 mg ASTELLAS PHARMA GMBH L04AA05 TACROLIMUSUM CAPS. 5 mg PROGRAF(R) 5 mg 5 mg ASTELLAS PHARMA GMBH L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 5 mg ADVAGRAF 5 mg 5 mg ASTELLAS PHARMA GMBH L04AA05 TACROLIMUSUM CONC. PT. SOL. PERF. 5 mg/ml PROGRAF(R) 5 mg/ml 5 mg/ml ASTELLAS PHARMA GMBH ________________________________________________________________________________
| 956 |L04AA06| MYCOPHENOLATUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA06 MYCOPHENOLATUM COMPR. FILM. GASTROREZ. 180 mg MYFORTIC 180 mg 180 mg NOVARTIS PHARMA GMBH
CELLCEPT 1 mg/5 ml 1 g/5 ml ROCHE REGISTRATION LTD. Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic L04AA06 MYCOPHENOLATUM CAPS. 250 mg CELLCEPT 250 mg 250 mg ROCHE REGISTRATION LTD. MYFENAX 250 mg 250 mg TEVA PHARMA BV
MYFORTIC 360 mg 360 mg NOVARTIS PHARMA GMBH L04AA06 MYCOPHENOLATUM CAPS. 500 mg MYFENAX 500 mg 500 mg TEVA PHARMA BV Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic L04AA06 MYCOPHENOLATUM COMPR. FILM. 500 mg CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD. L04AA06 MYCOPHENOLATUM PULB. PT. CONC. PT. 500 mg SOL. PERF. CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD. ________________________________________________________________________________ ______________________________________________________________________________ | 957 |L04AA10| SIROLIMUS** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA10 SIROLIMUS COMPR. FILM. 1 mg RAPAMUNE 1 mg 1 mg WYETH EUROPA LTD.
| 958 |A05AA02| ACIDUM URSODEOXYCHOLICUM | | |_______|_______|____________________________________________|_________________|
Yüklə 4,39 Mb. Dostları ilə paylaş:
|